Multiple endocrine neoplasia type 1 other imaging findings: Difference between revisions
No edit summary |
(Mahshid) |
||
(12 intermediate revisions by 4 users not shown) | |||
Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 1}} | {{Multiple endocrine neoplasia type 1}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Other imaging studies for multiple endocrine neoplasia type 1 include | Other imaging studies for multiple endocrine neoplasia type 1 include fluoro-di-glucose-[[PET]]/[[CT]], venous sampling, [[angiography]] and endovascular procedures, such as trans-arterial chemo-[[embolization]] (TACE). | ||
=== | ==Other imaging findings== | ||
* Common radiopharmaceutical is 111-indium-pentetreotide, which is a ligand for somatostatin receptor on the cell membrane of many | ===Nuclear Medicine=== | ||
* Can be used in combination with cross-sectional imaging modalities to aid staging e.g. SPECT or PET-CT or PET-MRI 6 | * Common radiopharmaceutical agent is 111-indium-pentetreotide, which is a [[ligand]] for [[somatostatin]] receptor on the [[cell membrane]] of many [[neuroendocrine tumor]]s. Multiple [[tumor]] sites and [[metastasis]] can be identified using a gamma-camera which detect the emitted [[radiation]]. | ||
* Can be used to predict response to nuclear medicine based therapies, and, in some cases, to assess response to treatment | * Can be used in combination with cross-sectional imaging modalities to aid staging e.g. [[SPECT]] or [[PET]]-[[CT]] or [[PET]]-[[MRI]]. <ref name="pmid27904855">{{cite journal| author=Park HL, Yoo IR, Kim SH, Lee S| title=Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT. | journal=Ann Surg Treat Res | year= 2016 | volume= 91 | issue= 6 | pages= 323-326 | pmid=27904855 | doi=10.4174/astr.2016.91.6.323 | pmc=5128379 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27904855 }} </ref> <ref name="pmid27904855">{{cite journal| author=Park HL, Yoo IR, Kim SH, Lee S| title=Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT. | journal=Ann Surg Treat Res | year= 2016 | volume= 91 | issue= 6 | pages= 323-326 | pmid=27904855 | doi=10.4174/astr.2016.91.6.323 | pmc=5128379 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27904855 }} </ref> | ||
* Care should be taken with interpretation of images as | * Can be used to predict response to nuclear medicine based therapies, and, in some cases, to assess response to treatment | ||
* | * Care should be taken with interpretation of images as [[drug]]s can interfere with somatostain receptor expression, e.g. [[interferon]]. | ||
* Gallium-68 labelled somatostatin analogues (PET/CT) | * [[Neuroendocrine tumor]]s can differentiate into [[tumor]]s that do not express [[somatostatin receptor]]s can become ‘image negative’ making reoccurrence or [[metastases]] more challenging to detect. Other radiopharmaceuticals are also used, based on certain physiological characteristics e.g. [[cell surface receptor]]s or uptake of molecules. | ||
* F18 DOPA and C11 | * Gallium-68 labelled somatostatin analogues ([[PET]]/[[CT]]) is thought to be more sensitive in detecting [[neuroendocrine tumor]]s except pulmonary and hepatic [[metastases]]. For aggressive, rapidly growing [[tumor]]s (i.e. high metabolism) fluoro-di-glucose-[[PET]]/[[CT]] can be used (FDG-PET). <ref name="pmid26242621">{{cite journal| author=Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M et al.| title=Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). | journal=Endocrine | year= 2016 | volume= 52 | issue= 3 | pages= 488-94 | pmid=26242621 | doi=10.1007/s12020-015-0702-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26242621 }} </ref> <ref name="pmid26206648">{{cite journal| author=Sadowski SM, Millo C, Cottle-Delisle C, Merkel R, Yang LA, Herscovitch P et al.| title=Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. | journal=J Am Coll Surg | year= 2015 | volume= 221 | issue= 2 | pages= 509-17 | pmid=26206648 | doi=10.1016/j.jamcollsurg.2015.04.005 | pmc=4515773 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26206648 }} </ref> <ref name="pmid28138732">{{cite journal| author=Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP et al.| title=Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1. | journal=World J Surg | year= 2017 | volume= 41 | issue= 6 | pages= 1521-1527 | pmid=28138732 | doi=10.1007/s00268-017-3907-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28138732 }} </ref> <ref name="pmid26905068">{{cite journal| author=Goroshi M, Bandgar T, Lila AR, Jadhav SS, Khare S, Shrikhande SV et al.| title=Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India. | journal=Fam Cancer | year= 2016 | volume= 15 | issue= 4 | pages= 617-24 | pmid=26905068 | doi=10.1007/s10689-016-9891-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26905068 }} </ref> | ||
==Invasive Imaging Techniques== | * F18 DOPA and C11 Hydroxy[[tryptophan]] may be used in future but are not routinely available. | ||
* Venous sampling can be used in small functional | |||
* Multiple endocrine neoplasia type 1 can present with multiple lesions. Functional | ===Invasive Imaging Techniques=== | ||
* Venous sampling can be used in small functional [[neuroendocrine tumor]]s where cross sec-tional imaging is equivocal. | |||
== | * Multiple endocrine neoplasia type 1 can present with multiple lesions. Functional [[neuroendocrine tumor]]s can be identified from these, using [[calcium]] stimulation with venous sampling. | ||
{{ | |||
==References== | |||
{{reflist|2}} | |||
[[Category:Oncology]] | |||
[[Category:Endocrinology]] | |||
[[Category: | {{WS}} | ||
{{WH}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] |
Latest revision as of 02:45, 27 November 2017
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 other imaging findings On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 other imaging findings |
FDA on Multiple endocrine neoplasia type 1 other imaging findings |
CDC on Multiple endocrine neoplasia type 1 other imaging findings |
Multiple endocrine neoplasia type 1 other imaging findings in the news |
Blogs on Multiple endocrine neoplasia type 1 other imaging findings |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Other imaging studies for multiple endocrine neoplasia type 1 include fluoro-di-glucose-PET/CT, venous sampling, angiography and endovascular procedures, such as trans-arterial chemo-embolization (TACE).
Other imaging findings
Nuclear Medicine
- Common radiopharmaceutical agent is 111-indium-pentetreotide, which is a ligand for somatostatin receptor on the cell membrane of many neuroendocrine tumors. Multiple tumor sites and metastasis can be identified using a gamma-camera which detect the emitted radiation.
- Can be used in combination with cross-sectional imaging modalities to aid staging e.g. SPECT or PET-CT or PET-MRI. [1] [1]
- Can be used to predict response to nuclear medicine based therapies, and, in some cases, to assess response to treatment
- Care should be taken with interpretation of images as drugs can interfere with somatostain receptor expression, e.g. interferon.
- Neuroendocrine tumors can differentiate into tumors that do not express somatostatin receptors can become ‘image negative’ making reoccurrence or metastases more challenging to detect. Other radiopharmaceuticals are also used, based on certain physiological characteristics e.g. cell surface receptors or uptake of molecules.
- Gallium-68 labelled somatostatin analogues (PET/CT) is thought to be more sensitive in detecting neuroendocrine tumors except pulmonary and hepatic metastases. For aggressive, rapidly growing tumors (i.e. high metabolism) fluoro-di-glucose-PET/CT can be used (FDG-PET). [2] [3] [4] [5]
- F18 DOPA and C11 Hydroxytryptophan may be used in future but are not routinely available.
Invasive Imaging Techniques
- Venous sampling can be used in small functional neuroendocrine tumors where cross sec-tional imaging is equivocal.
- Multiple endocrine neoplasia type 1 can present with multiple lesions. Functional neuroendocrine tumors can be identified from these, using calcium stimulation with venous sampling.
References
- ↑ 1.0 1.1 Park HL, Yoo IR, Kim SH, Lee S (2016). "Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT". Ann Surg Treat Res. 91 (6): 323–326. doi:10.4174/astr.2016.91.6.323. PMC 5128379. PMID 27904855.
- ↑ Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M; et al. (2016). "Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1)". Endocrine. 52 (3): 488–94. doi:10.1007/s12020-015-0702-y. PMID 26242621.
- ↑ Sadowski SM, Millo C, Cottle-Delisle C, Merkel R, Yang LA, Herscovitch P; et al. (2015). "Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1". J Am Coll Surg. 221 (2): 509–17. doi:10.1016/j.jamcollsurg.2015.04.005. PMC 4515773. PMID 26206648.
- ↑ Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP; et al. (2017). "Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1". World J Surg. 41 (6): 1521–1527. doi:10.1007/s00268-017-3907-9. PMID 28138732.
- ↑ Goroshi M, Bandgar T, Lila AR, Jadhav SS, Khare S, Shrikhande SV; et al. (2016). "Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India". Fam Cancer. 15 (4): 617–24. doi:10.1007/s10689-016-9891-7. PMID 26905068.